Plain-English translation of NCT03801434 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help people with rare blood disorders caused by abnormally high levels of eosinophils (a type of white blood cell). Researchers want to understand whether the medication can reduce the number of these cells and improve symptoms, and whether patients who take it can reduce or stop taking steroids. The trial will enroll about 10 patients and track their response over several months.
Many patients with these rare eosinophil disorders depend on steroids to manage their symptoms, but steroids can cause serious side effects with long-term use and don't work for everyone. This trial is exploring whether this medication offers a better or additional treatment option that might help patients reduce their steroid use.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice each day for up to 6 months, organized into 6 cycles of 4 weeks each. During this time, you will have regular clinic visits for blood tests and medical check-ups to monitor how well the treatment is working and watch for any side effects. The study team will track your eosinophil counts, any improvement in your symptoms, whether you can reduce or stop steroid medications, and how long any benefit lasts.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States